Literature DB >> 10546470

The oral glucose tolerance test in patients with respiratory infections.

O K Başoğlu1, F Bacakoğlu, G Cok, A Sayiner, M Ateş.   

Abstract

The aim of this study, carried out in a specialized centre for chest diseases in Turkey, was to determine the prevalence of glucose intolerance in tuberculosis (TB) and pneumonia so as to assess the specificity of the association of TB with diabetes mellitus. The study group comprised 58 active pulmonary TB patients without any history of diabetes mellitus and the matched control group consisted of 23 community-acquired pneumonia patients. An oral glucose tolerance test (OGTT) was performed at the time of diagnosis and 3 months after the treatment was started in both groups. Glucose intolerance was found in six (10.4%) patients and diabetes mellitus in five (8.6%) patients in the TB group. In the control group, four (17.4%) patients were found to be diabetic and none of them were glucose intolerant. There was no significant difference between the two groups (p > 0.05). There was a higher prevalence of abnormal OGTT results among elderly patients in both groups. OGTT results returned to normal in both the TB and pneumonia groups after treatment. The results suggest that glucose intolerance occurs in the setting of infection and is reversible following adequate antimicrobial treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10546470

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  22 in total

Review 1.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 2.  New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients.

Authors:  T Adepoyibi; B Weigl; H Greb; T Neogi; H McGuire
Journal:  Public Health Action       Date:  2013-11-04

3.  Tuberculosis-Related Diabetes: Is It Reversible after Complete Treatment?

Authors:  Huma Aftab; Dirk L Christensen; Atiqa Ambreen; Mohammad Jamil; Peter Garred; Jørgen H Petersen; Susanne D Nielsen; Ib C Bygbjerg
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

4.  SCALING UP NON-COMMUNICABLE DISEASE CONTROL: LESSONS TO BE LEARNT FROM THE INFECTIOUS DISEASE PARADIGM IN KENYA.

Authors:  A Njoroge; K E Munene
Journal:  East Afr Med J       Date:  2015-12

Review 5.  The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications.

Authors:  Laneke Luies; Ilse du Preez
Journal:  Clin Microbiol Rev       Date:  2020-07-01       Impact factor: 26.132

Review 6.  Convergence of non-communicable diseases and tuberculosis: a two-way street?

Authors:  M J Magee; A D Salindri; U P Gujral; S C Auld; J Bao; J S Haw; H-H Lin; H Kornfeld
Journal:  Int J Tuberc Lung Dis       Date:  2018-11-01       Impact factor: 2.373

7.  Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Benin.

Authors:  S Ade; D Affolabi; G Agodokpessi; P Wachinou; F Faïhun; N Toundoh; W Békou; A Makpenon; G Ade; S Anagonou; A D Harries
Journal:  Public Health Action       Date:  2015-06-21

Review 8.  Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.

Authors:  Anca Lelia Riza; Fiona Pearson; Cesar Ugarte-Gil; Bachti Alisjahbana; Steven van de Vijver; Nicolae M Panduru; Philip C Hill; Rovina Ruslami; David Moore; Rob Aarnoutse; Julia A Critchley; Reinout van Crevel
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09       Impact factor: 32.069

Review 9.  Diabetes and HIV.

Authors:  Emile Camille Noubissi; Jean-Claude Katte; Eugene Sobngwi
Journal:  Curr Diab Rep       Date:  2018-10-08       Impact factor: 4.810

Review 10.  Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.

Authors:  Helen McIlleron; Susan Abdel-Rahman; Joel Alex Dave; Marc Blockman; Andrew Owen
Journal:  J Infect Dis       Date:  2015-06-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.